Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Capecitabine and Radiation in High Risk Early Stage Breast Cancer
NCT00562718Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2004
- Primary completion
- Sep 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by UT Southwestern Medical Center. Primary endpoint: Overall Safety at 1 year. Started Sep 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00562718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562718.